HPAPI World Congress Agenda

 

Basel, 30 - 31 October 2018

Schedule

Create your personal agenda –check the favourite icon

Oct 2908:56
Conference pass

Chair's opening remarks

Keynotes
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Oct 2909:00
Conference pass

Innovation in CAR T

Keynotes
Pascal Touchon, Senior Vice President and Global Head Cell & Gene, Novartis
Oct 2909:00
Conference pass

What’s the most effective model for an organisation; internal, external, or hybrid?

Clinical Trials plenery
  • A case study of Merck’s shift from outsourcing to an internal focused model
  • Highlighting the pros and cons of different approaches
Oct 2909:00
Conference pass

An update on Pfizer’s biosimilar goals for 2019

Keynotes
  • Policies around sustainability after 10 years of biosimilars in Europe
  • Global presence in other regions, non-compatibles and standards
Oct 2909:20
Conference pass
Oct 2909:20
Conference pass

The future of clinical trials in an outsourced model

Clinical Trials plenery
Reserved for supporting partner- If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2909:20
Conference pass

The past, present, and future of antibody-drug conjugates

Keynotes
Oct 2909:20
Conference pass

The totality of evidence for the approval of biosimilar etanercept and rituximab

Keynotes
  • The concept of totality of evidence applied
  • Case studies for the development and assessment of biosimilar etanercept and rituximab
  • Tailoring biosimilar development in the future
Oct 2909:40
Conference pass

Advancements in antibody drug conjugates: therapeutic challenges of safety and efficacy

Keynotes
  • Next generation ADCs with improved antibodies, payload, linkers, conjugation technology
  • Lessons learned from the clinical development of ADCs
  • Maximizing efficacy while minimizing toxicities
  • ADC disposition, PK-PD challenges
  • Translational challenges to ADC development
  • Looking at the future of ADCs
Oct 2909:40
Conference pass

Keynote Panel Discussion- Disruptive procurement methods: choosing your CRO

Clinical Trials plenery
  • Multiple vs singular CRO input
  • Finding the balance between expertise and ethos
  • Pros and cons of different approaches
Oct 2909:40
Conference pass

Senior-level panel: Immunotherapy strategies for oncology

Keynotes
  • Short 5 minute presentations outlining strategies developing immunotherapy for oncology, given by 6 high level representatives from differing company sizes
  • Panel discussion talking about how strategies for cancer immunotherapy differ between companies, and advantages and disadvantages for both
  • Top level speakers representing big pharma, large biotech and mid-sized biotech
Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics
Emma Lees, Senior Vice President, Research, Jounce Therapeutics
Niklas Engler, Head of Technical Development Biologics for Europe, F. Hoffmann-La Roche AG
Oct 2909:40
Conference pass

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

Keynotes
    Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gain-sharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines
Oct 2910:00
Conference pass

Title to be confirmed

Keynotes
Senior Executive, Fujifilm Diosynth Biotechnologies
Oct 2911:20
Conference pass

Breakout sessions

Keynotes
WORKSHOP 1
Understanding issues around physician education and uptake
Host: Jonathan Underhill, Medicines Clinical Adviser, Medicines and Technologies Programme (MTP), NICE
Jatinder Harchowal, Chief Pharmacist / Clinical Director, Medicines Management & Clinical Support Services Business Unit, Pharmacy Dept, The Royal Marsden NHS Foundation Trust
James Kent, Regional medicine procurement specialist East of England, NHS England
Caroline Boulliat, Member of Biosimilar Medicine Programme Board, NHS England, NHS Clinical Commissioners, NICE

WORKSHOP 2
WHO Guidelines on Global reference product
Ingrid Schwarzenberger, Head Global Regulatory Affairs, Sandoz Biopharmaceuticals
Suzette Cox, Senior Director International - Biosimilar Medicines Group, Medicines for Europe
Mareike Ostertag, Director Science & Regulatory policy, Novartis

ROUNDTABLE 1
Tackling IP and Legal challenges
Stacie Ropka, Partner, Axinn, Veltrop & Harkrider LLP


ROUNDTABLE 2
Working with multi-cultural, global virtual teams to develop biosimilar products – Challenges and solutions
Shantreddy Soogareddy, Associate Director External R&D, Dr. Reddy's Laboratories SA.

ROUNDTABLE 3
Characterisation and analytics of products on the market
Tudor Arvinte, Owner, Therapeomic Inc.

ROUNDTABLE 4
Market access
Adam Levysohn, Sr Director Market Access Biosimilar, Biogen

ROUNDTABLE 5
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

ROUNDTABLE 6
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2911:30
Conference pass

Improving engagement with investigators and patients

Clinical Trials plenery
  • Improving the effectiveness of investigator meetings
  • Collaborating with investigators using digital technology
  • Engaging with patients in clinical trials
Tim Cave, VP-Head Strategic Planning and Digital Practices, Global Medical Affairs, GSK
Oct 2911:35
Conference pass

Plenary round table session

Keynotes
Table 1: Logistics and supply chain management for cell therapy
Table 3: Immunotherapy for solid tumours
Table 4: Biomarker discovery and development
Table 5: Scale-up and commercialisation of cell therapy products
Prentice Curry, Vice President Quality and Operations, Kite Pharma Inc
Table 6: Clinical trials for immunotherapy
Oct 2911:35
Conference pass

Plenary roundtable session

Keynotes
Table 1: Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
Table 2: Indication selection/expansion and early biomarker discovery for bispecifics
Table 4: Muilti-specific formatomics – how much format diversity is required to address biology and developability?
Table 5: Clinical trials for antibodies
Table 6: Safety and efficacy for protein therapeutics
Table 7: Advances in multiplexing for clinical diagnosis
Lee Dawson, Senior Scientist, Molecular Pathology Group, Asterand Bioscience
Table 8: Reserved for supporting partner
Table 9: Reserved for supporting partner
Oct 2911:50
Conference pass

Personalisation of Research

Clinical Trials plenery
  • Digital Platforms
  • Transparency and Openness
  • Adoption of new treatments
Oct 2912:10
Conference pass

Patient centricity and clinical innovation in oncology trials

Clinical Trials plenery
  • What patients actually want to read about in the informed consent documents
  • The value of patient input at all stages of a clinical programme, including protocol development
  • Insights from completing patient surveys mid-study
  • Novel approaches to deliver early phase trials that maximise patient benefit
Oct 2912:25
Conference pass

Speed Networking

Keynotes
A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings).
Oct 2912:30
Conference pass

Improving the state of clinical trials through patient centricity

Clinical Trials plenery
  • Patient’s involvement in regulation development
  • What are the challenges of patient engagement?
  • Patient education and support
Caroline Feys, Research & Development Operations Innovation (RDO-I) Leader, Jansen
Conference pass

Chair: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals

Track 1 - Biosimilar commercialisation
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Conference pass

Chair: Ian Henshaw, Global Head of Biogen’s Biosimilars Unit, Biogen

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 2914:10
Conference pass

Adapting to the new landscape for early clinical development in oncology

Clinical Trials plenery
  • Challenges for cancer early drug development
  • Key lessons and trends in oncology; combinations
  • Future oncology drug development solutions
Oct 2914:10
Conference pass

A first-in-class Treg depleting Ab for reversing immune suppression in tumours

Immune Checkpoint Inhibitors
  • Development of a first-in-class Ab for targeting Treg in cancer, from concept definition and demonstration (POC) to the identification and manufacturing of a clinical candidate for use in cancer patients
    • Concept identification
    • Concept demonstration
    • Ab screening and selection
    • Ab manufacturing
Oct 2914:10
Conference pass

Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye

Protein Engineering
  • Formulation and stability pose challenges for ocular biotherapeutics
  • Selection or re-engineering of protein therapeutics may be required for ocular delivery
  • Antibody Fab formulation and/or conjugation can be used to alter dosing frequency
Oct 2914:10
Conference pass

Immunoglobulin domain interface exchange as a platform technology to engineer bispecific antibodies

Bispecifics
  • Bispecific antibodies based on heavy chain hetero-dimerization
  • Common light chain format
  • Clinical stage antibodies
Conference pass

The role and future of biosimilars

Track 1 - Biosimilar commercialisation
  • Physicians’ perspective on early introduction of biologics
  • The future and role of biosimilars
  • Reducing cost and increase patient access
Houng Kim, head of the strategy and operations division, Celltrion Healthcare
Oct 2914:10
Conference pass
Oct 2914:10
Conference pass

Antibody-tubulysin conjugates display activity in MDR+ and bystander activity models

Armed Antibodies
  • Tubulysin M and stabilized analogues were compared as ADC payloads
  • Quaternary ammonium-linked tubulysin linkers were evaluated for activity in models of multidrug resistance and antigen-heterogeneity
  • Tubulysin linkers are a promising payload class, combining potency in MDR+ and antigen-heterogeneous tumor models in a structure-dependent manner
Conference pass

Biosimilars uptake and market considerations in the EU

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 2914:10
Conference pass

Bioassays for therapeutic proteins: design, validation and beyond

Regulation and Investment
  • Bioassays are an integral component of quality control testing in the development of therapeutic proteins, including monoclonal antibodies.
  • Assay acceptability depends on product type, mechanism of action, associated risk, phases of development, and availability of other quality data
  • This presentation provides regulatory expectations on bioassays with case studies highlighting the relevant issues commonly seen in the regulatory submissions
Oct 2914:30
Conference pass

Clinical operations: what does it take to get a cellular therapy trial planned, organised and initiated?

Clinical Trials plenery
  • Operations experience from a Phase II CAR T development study
  • What do we need to do as an industry when we look at cell therapy trials?
  • How does an organisation recalibrate tools and methodologies to meet demands of these types of trials?
Oct 2914:30
Conference pass

Structural and functional role of antibody variable domain glycosylation

Protein Engineering
  • What is the impact of variable domain glycans on structural aspects of IgG?
  • How do variable domain glycans shape the repertoire of antibody responses?
  • How is the functionality and immunobiology of IgG modulated by variable domain glycans?
Oct 2914:30
Conference pass

Analytical characterisation of BEAT bispecific antibodies

Bispecifics
  • Glenmark’s BEAT technology features heterodimerisation of heavy chain by bio-mimicry
  • scFv x FAB format allows for versatile combinations without use of common light chain
  • BEAT molecules have unique features – beneficial for manufacturing process, and requiring appropriate application of analytical techniques
  • This presentation would provide an overview of analytical techniques used for BEAT molecules, compared to “classic” monoclonal antibodies
Conference pass

Case Study: Biosimilar development in Russia and EuroAsian Union

Track 1 - Biosimilar commercialisation
Oct 2914:30
Conference pass

Costimulatory T-Cell engagement by the 4-1BB/HER2 bispecific PRS-343 for tumor localized activation of the immune system

Cell Therapy
Oct 2914:30
Conference pass

Reserved for Supporting Partner

Cell Therapy
Reserved for supporting partner
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Conference pass

Oncology biosimilars: the vastly evolving HTA landscape

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Biosimilar national HTA archetypes
  • Integrating Biosimilars in the therapeutic strategy:
  • Reimbursement in extrapolated indications, reimbursement of a biosimilar when the originator was not cost-effective, pharmacy substitution
  • Hospital-Based HTA for Biosimilars: How do providers and hospitals decide which biosimilar to list on their formulary?
Oct 2914:30
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2914:30
Conference pass

An FDA update – antibodies and biologics

Regulation and Investment
Oct 2914:50
Conference pass

Standardization efforts in clinical development focused on the “what” and not the “how”

Clinical Trials plenery
  • CDISC standards, protocol templates, and government registries share what trials are run, data collected, and standardized submissions. Information on how clinical research is designed tends to be captured ad-hoc, making it difficult to find not just externally, but even within organizations
  • Proposal for a clinical development design information model
  • Merits for capturing design thinking in a structured manner
  • Past and current projects ongoing to establish a clinical development design information model, and framework
Oct 2914:50
Conference pass

Engineering of highly selective anti- Aβ42 antibody with picomolar affinity for the treatment of Alzheimer’s disease

Protein Engineering
Chris Lloyd, Senior Scientist, Protein Engineering, Antibody Discovery and Protein Engineering, MedImmune U.K. Ltd
Oct 2914:50
Conference pass

Targeting immune checkpoints with Humabody VH therapeutics

Immune Checkpoint Inhibitors
  • Outline approach to developing differentiated Immuno oncology therapeutics
  • BiParatopic PD-1 inhibitor which shows efficacy in an anti-PD-1 insensitive in vivo model
  • BiSpecific molecule inhibiting both PD-1 and LAG3 for overcoming resistance or insensitivity to PD-1 inhibition
  • Targeted IO approach in which T-cell co-stimulation is focused away from the periphery and into the tumour microenvironment in order to improve the narrow therapeutic index observed with standard T-cell agonist antibodies
Phil Bland-Ward, Chief Scientific Officer, Crescendo Biologics Ltd
Conference pass

Navigating the development journey - from choosing the right cell line to entering commercialization

Track 1 - Biosimilar commercialisation
  • From cell line to commercialization – understanding the questions of which molecules, which markets, how and when
  • Analysing product development - cell lines vs cell lineswith process; in-house vs outsourced or combination;case studies/examples from the biosimilar world
  • How small companies can cope with increasing qualityexpectations from agency
  • Leveraging the external expertise to decrease the timeline to commercialization
Dinesh Kundu, General Manager of Strategy, Business Development and Program Management, Intas Biopharmaceuticals
Oct 2914:50
Conference pass

Reserved for supporting partner

Bispecifics
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2914:50
Conference pass

Reserved for Supporting Partner

Cell Therapy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2914:50
Conference pass

Development of potent and efficacious with payloads that target tubulin

Armed Antibodies
  • Payload and linker development
  • In vitro screening
  • In vivo efficacy
Conference pass

Sustaining the value proposition of biosimilars

Track 2 - Biosimilar Sustainability/Development and manufacturing
Erin Federman, VP, Head of Biologics, Boehringer Ingelheim
Oct 2914:50
Conference pass

When the cake gets small: broad antibody claims in a crammed field

Regulation and Investment
  • The breadth of allowable claims depends on the available prior art
  • A well characterized epitope may form the basis of a broad claim
  • Broad antibody composition claims
  • Good fall back position needed in case of attack in Opposition proceedings
Dr Helena Domingues, Examiner, Joint Cluster Biotechnology, Immunology Directorate, European Patent Office
Oct 2915:10
Conference pass

Clinical Protocol feasibility as key activity for success: experiences from different Therapeutic Areas

Clinical Trials plenery
  • Medical feasibility
  • Regulatory challenges
  • Operational challenges and implementation
Fabio Baschiera, Functional Head Of Clinical Development, Oncology And Hematology, Novartis
Oct 2915:10
Conference pass

IgA antibodies for the recruitment of myeloid effector cells in tumour immunotherapy

Immune Checkpoint Inhibitors
  • Myeloid cells constitute a significant population of the tumour immune cell infiltrate
  • Antibodies of IgA isotype effectively activate tumour cell killing by myeloid cells
  • Tumour cell killing by myeloid cells is enhanced by blockade of CD47/SIRPa interactions
Oct 2915:10
Conference pass

Reserved for Isogenica

Protein Engineering
Oct 2915:10
Conference pass

ATOR-1015 is a CTLA-4 x OX40 bispecific immune activating antibody developed for tumor-directed immunotherapy

Bispecifics
  • ATOR-1015 binds both targets simultaneously, promoting cell-cell interactions expected to enhance the immuno-stimulating effects
  • The mode of action of ATOR-1015 is a combination of regulatory T cell (Treg) depletion and effector T cell activation
Conference pass

Developing a biosimilar in an emerging market

Track 1 - Biosimilar commercialisation
Speaking slot available
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2915:10
Conference pass

New approach for old target: W0101 antibody drug conjugate effectively inhibits tumour growth in pre-clinical models of IGF-1R over-expressing solid tumours

Armed Antibodies
Nathalie Corvaïa, Managing Director, Institut De Recherche Pierre Fabre
Conference pass

Panel discussion: How can we sustain the value proposition of biosimilars in the future as an industry?

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 2915:10
Conference pass

Reserved for supporting partner

Regulation and Investment
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Conference pass

Chair: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals

Track 1 - Biosimilar commercialisation
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Conference pass

Chair: Aidan Fry, Editor, Generics & Biosimilars News

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 2916:30
Conference pass

Data-Driven Patient Recruitment with Real World Data at Roche pRED

Clinical Trials plenery
  • Data-Driven Recruitment (DDR) team at Roche Pharm Research & Early Development (pRED) would like to share our experience of integrating RWD (e.g. insurance claims, EMR) with trial metrics data to optimize study protocol design and target patient recruitment strategy
  • While the team has received positive feedback from our business partners (translational medicine, clinical program teams, and study leaders), we would like
Oct 2916:30
Conference pass

Antibody-cytokine fusions for cancer therapy

Immune Checkpoint Inhibitors
  • Antibody-cytokine fusions based on IL2, TNF or IL12: preclinical results
  • Results of on-going clinical trials
  • Rationale for combinations
Oct 2916:30
Conference pass

Efficient and safe antibody delivery across the blood brain barrier

Protein Engineering
  • The cerebrovascular network constitutes an efficient route for biologics to the brain
  • Engagement with the Blood Brain Barrier receptor crucial for efficient brain exposure
  • Antibodies with full effector function can be delivered in a stealth mode to the brain
Oct 2916:30
Conference pass
Oct 2916:30
Conference pass

Development of highly potent Anti-P-cadherin/Anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer

Bispecifics
Oct 2916:30
Conference pass

Efficient Development of Biosimilars - The importance of making your biosimilar development as specific, consistent and sensitive as possible

Track 1 - Biosimilar commercialisation
  • Case study of pegfilgrastim biosimilar
  • Understanding how we can build a bridge between the originator and biosimilar product using a specific, consistent and tailor-made approach
  • The importance of sensitivity to detect differences
  • Collaborating with regulatory affairs
Ruediger Jankowsky, Managing Director, Cinfa Biotech
Oct 2916:30
Conference pass

Radioimmunologic armed antibodies for solid tumours

Armed Antibodies
Anna Tafuri, Medical Director, Translational Medicine Oncology, Bayer HealthCare
Oct 2916:30
Conference pass

Upstream production platform for biosimilars - reserved for Dyadic

Track 2 - Biosimilar Sustainability/Development and manufacturing
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2916:50
Conference pass

Patient engagement to support recruitment and retention in clinical trials

Clinical Trials plenery
  • Early involvement of patients drives efficient clinical operations
  • Patients insights included in the total trial burden assessment for participants
  • “Nice to have” vs “need to have” assessment: trade-offs and risks
Oct 2916:50
Conference pass

Next generation cancer immunotherapy using IL-2/antibody complexes

Immune Checkpoint Inhibitors
  • Present our re-direct strategy to increase the efficacy of IL-2 therapy and decrease toxicity
  • Antibody development and in vitro data
  • In vivo data in mice (and possibly monkeys)
  • Late pre-clinical development activities
Oct 2916:50
Conference pass

Research and development strategy in immuno-oncology

Cell Therapy
Dr David Gilham, Vice President of Research and Development, Celyad
Oct 2916:50
Conference pass

Protein-polymer conjugation to increase residence time of a Fab therapeutic in the eye

Armed Antibodies
  • Understanding the role that hydrodynamic size plays in clearance from the vitreous
  • Polymer-Fab conjugation as a strategy for extending size
  • Development of a accompanying biophysical toolbox
Oct 2916:50
Conference pass

Panel: Investors in biologics

Regulation and Investment
  • What do investors look out for in start-ups?
  • What are the current trends for biologics?
  • Where do we see the industry moving to in the next 5-10 years?
  • How can you gain investment?
Dani Bach, Director, Healthcare Ventures, Touchstone Ventures
Oct 2916:55
Conference pass

Developing a biosimilar in an emerging market

Track 1 - Biosimilar commercialisation
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2916:55
Conference pass

Case study: CMC and manufacturing biosimilars for checkpoints inhibitors

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Modulating the upstream process to get biosimilarity without losing productivity
  • Achieving successful quality modulation
  • Novel SPOT technology to increase productivity
  • The dangers of higher cell densities, clarification and increasing specific productivity
Oct 2917:10
Conference pass

Patient recruitment strategy from a site’s point of view

Clinical Trials plenery
  • Patient focus groups and early involvement in protocol design
  • Strategy planning
  • Social networking tools
  • Simplifying study language for readability
  • What can sponsors do to help?
Oct 2917:10
Conference pass

Antibody engineering to overcome antigen mediated clearance in vivo

Protein Engineering
  • Antibodies targeting membrane bound antigens with a high rate of synthesis are rapidly eliminated from plasma by antigen mediated clearance, thus compromising their therapeutic utility
  • We present a case study to describe a protein engineering approach to generate a pH dependent binding antibody directed to a receptor
  • The resulting antibody has an extended half-life in vivo and its efficacy is not limited by dose
Claire Dobson, Associate Director of Antibody Discovery and Protein Engineering, MedImmune
Oct 2917:10
Conference pass

ImmTAC(TM) technology platform: novel strategies to increase immunotherapy efficacy

Immune Checkpoint Inhibitors
  • Generating high-affinity, bi-specific TCR-molecules for cancer therapy
  • Addressing intra-tumour heterogeneity
  • Strategies to enhance tumour immunogenicity
Oct 2917:10
Conference pass

Reserved for supporting partner

Bispecifics
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2917:10
Conference pass

Reserved for supporting partner

Cell Therapy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2917:10
Conference pass

Differentiating DeBouganin’s MOA from small molecules as ADC payloads

Armed Antibodies
  • The In vitro potency of deBouganin versus that of traditional small molecule drugs as payloads for tumour-targeted therapeutics (ADCs) will be discussed
  • Data will be presented demonstrating that deBouganin induces biomarkers associated with immunogenic cell death and does not enrich the presence of immunosuppressive cell surface markers
  • The presented studies will support the use of DeBouganin-loaded ADCs to both directly kill tumour cells and spark host immune responses that could pair well with the use of checkpoint inhibitors
Oct 2917:20
Conference pass

Biosimilars in ophthalmology: Economy Vs Efficacy

Track 1 - Biosimilar commercialisation
Sandesh Warudkar, Medical Advisor, Cadila Healthcare Ltd
Oct 2917:20
Conference pass

Case Study: CMC, development, differentiation and formulation for orphan biosimilars

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Clinical studies to show biosimilarity of own formulations
  • Better compliance
  • Outsourcing manufacturing
Andreas Herrmann, Chief Executive Officer, Valerius Biopharma
Oct 2917:30
Conference pass

Panel Discussion: what are the biggest hurdles in clinical trial recruitment and how can they be solved?

Clinical Trials plenery
  • Which tools can be used to ease the enrolment process?
  • What are the biggest factors contributing to patients and investigator concerns?
  • Should social media be embraced more?
Oct 2917:30
Conference pass

Physical stability – structural homogeneity of biotherapeutic antibodies: property prediction by in silico methods

Protein Engineering
  • Discovery and development of biotherapeutic mAbs is a multiparametric optimization to balance biological and pharmaceutical properties such as stability
  • Stability refers to intricate structural, chemical, and physical processes. Methods for theoretical prediction of these processes generally focus on particular aspects, not on the global outcome of such modifications
  • We will report on a knowledge-based approach to predict aspects of stability by combining homology modelling, structural descriptor calculations, and classification algorithms
Oct 2917:30
Conference pass

Bispecific DART® Molecules in the age of cancer immunotherapy: redirected T cell killing and beyond

Bispecifics
  • Notwithstanding recent progress, unmet needs still exist in immunotherapy of cancer
  • Bispecific molecules may offer unique opportunities to address such needs
  • Application of the DART platform in redirected T‐cell killing, checkpoint blockade and co‐stimulation will be presented
Oct 2917:30
Conference pass

Reserved for supporting partner

Cell Therapy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2917:30
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2917:30
Conference pass

Modern analytical development of biologics

CMC and Developability
  • Feasibility of modern analytical tools for biologics development
  • Innovative approaches for process analytics
  • Trends and upcoming requirements for the analytical control of biopharmaceuticals
Oct 2917:50
Conference pass

Mechanistic insight into transferrin receptor-mediated BBB shuttling antibodies based on VNARs

Protein Engineering
  • Novel approach for discovery of BBB penetrating antibodies
  • Optimisation of efficacy of BBB transporters
  • Mechanistic requirements for VNAR-based BBB shuttling antibodies
Oct 2917:50
Conference pass

Selective SIRP-alpha antibodies: next-generation checkpoint inhibitors of myeloid cells

Immune Checkpoint Inhibitors
  • SIRPα is known as a myeloid cells checkpoint controlling macrophage phagocytosis of CD47-expressing targets.
  • SIRPα also controls antigen uptake, processing and cross-presentation in dendritic cells, as well as chemokine secretion and motility of macrophages, thereby indirectly modulating intensity and location of T cell responses.
  • Selective SIRPα antagonist antibodies have been shown to increase anti-tumor T cell responses in orthotopic cancer models, to increase intratumor cell migration and to synergize with anti-PD1/PDL1 antibodies.
  • Boehringer Ingelheim and OSE Immunotherapeutics entered into a global license and collaboration agreement in immuno-oncology to develop OSE-172/BI765063, a novel selective SIRPα antagonist antibody.
Oct 2917:50
Conference pass

BiTE® antibody constructs in clinic and development

Bispecifics
  • Following the approval of blinatumomab in relapsed/refractory ALL multiple BiTE candidates have entered or are about to enter the clinic in various indications
  • Give an update on Amgen’s BiTE pipeline at the discovery, translational, and early clinical stage of development
Oct 2917:50
Conference pass

Reserved for supporting partner

Cell Therapy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 2918:10
Conference pass

Structure guided rational design of de novo antibody specificity

Protein Engineering
  • Engineered rat specificity de novo into Amgen’s lead anti-migraine molecule (AMG334
  • Fine tuning of specificity to gain Rat specificity without losing the human one
  • Structural computational approach, used in parallel with other engineering yielding the best results in terms of time vs effort vs cost
  • Investigated deep sequencing to enhance and de-risk the Ab engineering process
Oct 2918:10
Conference pass

The role of Fc receptor-IgG interactions in the therapeutic activity of checkpoint antibodies

Immune Checkpoint Inhibitors
  • FcR pathways involved in the therapeutic mechanism of different checkpoint mAbs
  • Harnessing Fc Receptors for optimizing the anti-tumour activity of checkpoint mAbs
  • Mouse models to study efficacy and toxicity of human checkpoint mAbs and for screening Fc-engineered clinical candidates.
  • Strategies to widen the therapeutic window of immunomodulatory mAbs
Oct 2918:10
Conference pass

Harnessing nanotechnology to engineer immune function

Cell Therapy
  • Use of nanotechnology and engineered materials to understand immune processes
  • Programmable activation of combinations of immune pathways for synergistic potency
  • Generation of antigen-specific tolerance to combat multiple sclerosis and type 1 diabetes
Christopher Jewell, Associate Professor & Damon Runyon-Rachleff Innovator, University of Maryland
Oct 2918:10
Conference pass

Identification of a DP-L1 binding FCAB: A potent inhibitor of immunosuppressive signals

Bispecifics
  • F-star has produced an Fcab, an antibody Fc domain modified to bind to a target, specific to PD-L1 The Fcab exhibits high affinity to human PD-L1 that translates into strong potency in cell-based functional assays
  • An anti-murine surrogate molecule, with similar potency, also exhibits activity in an MC38 syngeneic tumour model. This activity is improved when the Fcab is paired with Fabs targeting other immune checkpoint regulators
Oct 2918:10
Conference pass

DARPin-photosensitizer conjugates for EpCAM-directed photodynamic therapy of ovarian cancer

Armed Antibodies
  • Designed ankyrin repeat proteins
  • Photodynamic therapy
  • Ovarian cancer
  • Epithelial cell adhesion molecule (EpCAM)
Oct 2918:10
Conference pass

Developability assessment of therapeutic proteins – a toolbox for tackling increasing complexity

CMC and Developability
  • The concept of developability assessment of therapeutic proteins
  • Analytical challenges upon the shifting of biologics portfolio
  • Strategies and tool-box addressing the new demand
  • Case studies highlighting the analytical method development

Create your personal agenda –check the favourite icon

Conference pass

Chair: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals

Keynotes
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Oct 3009:00
Conference pass

Keynote panel: Combination therapy strategies

Keynotes
  • Combination therapies – what are the next steps?
  • Toxicity and efficacy
  • Latest research and news
Partha Chowdhury, Senior Director and Head, Antibody Discovery, Sanofi Genzyme
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
Deborah Charych, Executive Director, Nektar Therapeutics
Oct 3009:00
Conference pass

Keynote panel: Combination therapy strategies

Keynotes
  • Combination therapies – what are the next steps?
  • Toxicity and efficacy
  • Latest research and news
Deborah Charych, Executive Director, Nektar Therapeutics
Partha Chowdhury, Senior Director and Head, Antibody Discovery, Sanofi Genzyme
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
Oct 3009:00
Conference pass

The rise of the digital clinical trial

Clinical Trials plenery
  • The global outlook of revolutionary technology for clinical trials
  • Exciting updates from Pfizer’s implementation of blockchain for clinical trials
  • What’s slowing down take up of technology in the pharma industry?
Oct 3009:05
Conference pass

Reinventing the regulatory acceptance criteria for pharmaceuticals and biopharmaceuticals—making them more accessible

Keynotes
  • Time to revisit the scientific rationale for approving generics and biosimilars—breaking out from tradition and rote practice
  • Encouraging fast to market approaches—a challenge for both developers and FDA
  • Making “what is clinically meaningful” truly meaningful-- a new class of substitutable biosimilars and compliant generics
Oct 3009:20
Conference pass

Cross-Industry Collaboration evaluating how Blockchain can Transform the Pharmaceutical and Healthcare Industry, part of Emerging Trends & Technology PhUSE Workgroup

Clinical Trials plenery
  • Understanding the landscape in the pharma and healthcare settings
  • Exploring the areas where Blockchain could be used
  • Presenting two detailed use cases (a. Drug Supply Chain using Smart Contracts; b. Patient Data Access/Transparency) to support future development and implementation for proof of concept
Disa Lee Choun, Director, Head of Data Acquisition, UCB
Oct 3009:30
Conference pass

Keynote: Tackling issues with submissions relating to Module 3 from FDA experiences, including but not limited to the analytical similarity section

Keynotes
  • Areas that have been problems across sponsors for 351k applications
  • TBC: FDA Guidance on statistics for the analytical similarity assessment
  • What pre-clinical and clinical data may be necessary to support a designation as an interchangeable biosimilar?
  • What is the impact of the interchangeable designation on US state pharmacy practice and what are potential solutions to these issues
Oct 3009:40
Conference pass

Blockchain technology for improving clinical research quality

Clinical Trials plenery
  • How can blockchain improve reproducibility, data sharing, personal data privacy concerns and patient enrolment?
  • Core functionalities of blockchain applied to clinical trials
  • Impacts and implications
Oct 3009:55
Conference pass

Ensuring success with biosimilar approval in the US and globally

Keynotes
Speaking slot available
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

Oct 3010:00
Conference pass

Panel discussion hosted by Medidata

Clinical Trials plenery
Oct 3010:00
Conference pass

Reserved for supporting partner

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3010:00
Conference pass

Reserved for Supporting Partner

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3011:25
Conference pass

Insights into the molecular basis of a bispecific antibody’s target and tumor-targeting selectivity

Protein Engineering
Oct 3011:25
Conference pass

Tumour metabolism and immune checkpoint inhibitors

Immunotherapy for solid tumours
Oct 3011:25
Conference pass

Antibody discovery considerations for ImmunoOncology bi-specific molecules

Bispecifics
  • Antibody Discovery
  • T-cell Engager modalities
  • Bi-Specific scaffolds
Oct 3011:25
Conference pass

Biosimilars: Current requirements and experience with EU and FDA approvals

Track 1 - Biosimilar commercialisation
Panel Discussion on regulation followed by questions from the audience
Oct 3011:25
Conference pass

Closed systems for CAR T-cell production

Manufacture, logistics and supply chain
Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics
Oct 3011:25
Conference pass

Global reference product in biosimilar development

Track 2 - Biosimilar Sustainability/Development and manufacturing
Suzette Kox, Senior Director Of International For Biosimilar Medicines Group, Medicines for Europe A.I.S.B.L.
Oct 3011:25
Conference pass

Pre-clinical development of HuMax-AXL-ADC

Armed Antibodies
  • Axl as a therapeutic target in human cancers
  • HuMax-AXL-ADC antibody generation and mechanism of action
  • Efficacy data for HuMax-AXL-ADC in preclinical models
Oct 3011:25
Conference pass

Cutting edge analytical and multiple attributes methods for mAbs and ADCs

CMC and Developability
  • 2 to 4D - LC-MS profiling and structure assessment
  • Insights gained from native, Ion Mobility, HILIC and CE mass spectrometry
  • Forced degradation, developability and comparability workflows
Oct 3011:25
Conference pass

Further advancement for human antibody discovery

Technology Showcase
  • Technological developments for human antibody discovery and optimization platform
Oct 3011:30
Conference pass

Minimising duplication of resources between BioPharma and service providers teams whilst managing risk

Clinical Trials plenery
Oct 3011:45
Conference pass

The importance of antibody isotype and Fc receptor interactions in engineering cancer immunotherapies

Protein Engineering
  • Immunomodulatory mAb can employ multiple mechanisms in tumours
  • Potential mechanisms depend on mAb isotype and FcγR availability
  • mAb engineering can allow multiple mechanisms to be engaged to therapeutic effect
Oct 3011:45
Conference pass

T-SIGn viruses: systemic delivery of localised combination immuno-gene therapy within the tumour microenvironment

Immunotherapy for solid tumours
  • T-SIGn platform: transgene-bearing genetically modified variants of enadenotucirev, an oncolytic chimeric group B adenovirus with clinical data demonstrating virus delivery to tumours following systemic dosing
  • Up to 4 different transgenes have been encoded in a single virus, enabling the design of candidates expressing combinations of biological agents for targeted immunotherapy
  • Local production of therapeutic combinations by tumour cells infected with the T-SIGn virus enables high local production for increased activity while minimizing systemic exposure for improved safety
Oct 3011:45
Conference pass

Cell therapy supply chain management, logistics and scale out

Manufacture, logistics and supply chain
  • Shipper suitability, features and options
  • Maintaining chain of custody for starting material and product
  • Logistics reliability and options
  • Supply chain sustainability and scale-out
Oct 3011:45
Conference pass

Targeted bispecific for treatment of inflammatory diseases

Bispecifics
  • Improving therapeutic potential of bio-therapeutics by increasing drug concentrations to target tissues and limiting systemic exposure
  • A case study using a preclinical model of autoimmune arthritis will be presented
  • Use of customized protein database generated from RNA-Seq data to increase proteome coverage and validate novel isoforms for biomarker discovery
Dr Ivan Mascanfroni, Senior Scientist, Immunology Biologics, AbbVie
Oct 3011:45
Conference pass

Preclinical evaluation of novel ADCs for ImmunoGen’s oncology pipeline

Armed Antibodies
Stuart Hicks, Associate Director, ImmunoGen Inc
Oct 3011:45
Conference pass

Tackling patient and investigator recruitment challenges for real world biosimilars study

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Generating evidence for market authorisation
  • Safety and efficacy considerations
  • Premarket authorisation trial
Oct 3011:45
Conference pass

Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands

Technology Showcase
  • Soluble cancer therapeutics consisting of a T-cell recruiting antibody fused to affinity maturated and highly selective TCR domains capable of targeting tumor-specific peptides presented by HLA class I
  • TCR discovery and affinity maturation, which allow the generation of highly affine and specific TCRs against tumor-specific HLA-bound peptides as identified and validated by our target discovery engine XPRESIDENT®
  • Obtain highly potent TCR bispecifics with picomolar activity against different tumor cell lines showing endogenous expression of the target peptide while exhibiting no reactivity towards cells lacking target peptide expression
Oct 3011:50
Conference pass

The Evolution of the FSP and Risk Based Study Execution

Clinical Trials plenery
  • How can processes evolve in an FSP model
  • How does operating in an FSP model facilitate implementation of Risk Based Study Execution?
  • Oversight of the suppliers within an FSP framework
Oct 3012:05
Conference pass

Biophysical characterization of bispecific antibodies for enhancement of dual-targeting specificity

Protein Engineering
  • Immunomodulatory mAb can employ multiple mechanisms in tumours
  • Potential mechanisms depend on mAb isotype and FcγR availability
  • mAb engineering can allow multiple mechanisms to be engaged to therapeutic effect
Ulrich Rant, Chief Executive Officer, Dynamic Biosensors
Oct 3012:05
Conference pass

Bispecific development

Immunotherapy for solid tumours
Jonathan Back, Deputy Director, Project Team Lead, Drug Discovery, Glenmark Pharmaceuticals SA
Oct 3012:05
Conference pass

Biosimilars from a regulator’s perspective: the current European situation

Track 1 - Biosimilar commercialisation
  • Update of the EU biosimilar guidelines -Current EMA regulatory status in Europe (biosimilars approved / under evaluation, and trends for scientific advices)
  • Frequent concerns (extrapolation, traceability, SmPC labelling and interchangeability)
Ingrid Bourges, Clinical Assessor, Federal Agency for Medicines and Health Products
Oct 3012:05
Conference pass

Next generation bispecific antibodies

Bispecifics
Oct 3012:05
Conference pass

Reserved for supporting partner

Manufacture, logistics and supply chain
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3012:05
Conference pass

Real world evidence on the interchangeability of reference products and biosimilars

Track 2 - Biosimilar Sustainability/Development and manufacturing
Gianluca Trifirò, Assistant Professor of Pharmacology, University of Messina
Oct 3012:05
Conference pass

Establishing highly precise, low material consuming biophysical platform for biologics developability assessment

CMC and Developability
  • New biophysical applications for Biologics characterization using
    • Second Harmonic Generation (SHG)
    • Nano Digferential Scanning Fluorimetry (nano-DSF)
    • Microscale Thermophoresis (MST)
  • Kinetics for thermal stability and Activation energy barrier determination for Biologics stability assessment
  • Long-terms stability prediction by computational biophysical approaches
Oct 3012:10
Conference pass

Clinical Operations Strategic Partnerships with CROs

Clinical Trials plenery
  • Obstacles implementing a Risk Based Plan
  • Risk mitigation plans, activities, and risk response
Oct 3012:25
Conference pass

Creating multifunctional VH-based biologics using Humabodies from the Crescendo Mouse

Protein Engineering
  • Proprietary transgenic mouse generates highly diverse fully human VH domain (‘Humabody’) building blocks
  • Fully modular plug & play approach lacks the constraints of traditional mAbs and enables a radical rethink of how a multifunctional molecule can be designed and assembled to deliver enhanced therapeutic benefit.
  • Examples of differentiated biology will focus on applications in immuno-oncology and Humabody drug conjugates
Oct 3012:25
Conference pass

Title TBC

Immunotherapy for solid tumours
Oct 3012:25
Conference pass

Application of the novel heterodimerization plattform Fc1k in mono- and multispecific molecules

Bispecifics
  • Principles of the novel heterodimerization strategy
  • Generation of a lead candidate as platform module
  • Examples for bispecific applications
  • Future opportunities
Oct 3012:25
Conference pass

Development of endogenous and engineered TCR-T cell therapies for solid cancers

Manufacture, logistics and supply chain
  • Immatics has a proprietary tumor antigen targets discovery platform, XPRESIDENT® which identifies tumor targets and screen TCRs against off-target toxicities
  • Endogenous and engineered TCRs against these tumor targets are used in Immatics’ Adoptive Cellular Therapy programs
  • IMA101 is a multi-product endogenous T cells against a warehouse of targets against various solid cancers currently in phase 1 clinical trial
  • IMA201, 202, and 203 are individual TCR engineered T cell products in various phase 1 trials for various solid cancers
  • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, and IMA202)
  • Manufacturing for 3 trials in progress and a 4th is in progress
Oct 3012:25
Conference pass

Panel discussion: Equity of access to biologic medicines across Europe

Track 1 - Biosimilar commercialisation
  • Expanded access to biologic drugs; the last piece of the biosimilar puzzle.o How can health systems expand access to biologic medicines for patients?
  • Updating clinical / prescribing guidelines:o How to increase access for patients through the updates of prescribing guidelines with the introduction of more cost-effective biosimilars? Biosimilars as a mean to break prescribing restrictions.
  • Are health systems missing out on the biosimilar opportunity?o How does the cost effectiveness of biosimilars compare to an average new drug?
Oct 3012:25
Conference pass

Functional disulfide re-bridging enables native full antibody DAR 2, 4 & 8 formation, site-selective orthogonal dual modification and homogeneous fragment drug conjugates

Armed Antibodies
  • Site-selective modification of antibodies (including robust serum stability, in vitro selectivity, in vivo efficacy with options for DAR 2, 4 & 8, dual drug conjugates and fragment drug conjugates).
  • Use of chemical linkers to form bi- and tri-specific scaffolds 3. Application of technology to generate oriented antibody fragments on nanoparticle surfaces
Oct 3012:25
Conference pass

Panel discussion: Clinical trials – do we need them to get biosimilars approved?

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Clinical trials vs pharmacology studies, what does the current FDA and EU guidance say?
  • Clinical pharmacology studies: efficacy & safety
  • Future possibilities
  • Q + A with the audience
Suzette Kox, Senior Director Of International For Biosimilar Medicines Group, Medicines for Europe A.I.S.B.L.
Gianluca Trifirò, Assistant Professor of Pharmacology, University of Messina
Oct 3012:25
Conference pass

Globally-optimised clinical candidates for maximised development success

CMC and Developability
  • Many therapeutic antibody candidates carry unnecessary amino-acid content in their binding domains
  • This extraneous content leads to significant proven CMC and clinical development risks
  • This presentation will present novel data translating fundamental antibody biology insights into improved-quality product candidates
Oct 3012:30
Conference pass

Panel Discussion- Site selection challenges and solutions

Clinical Trials plenery
  • How to improve communication between sites, sponsors and CROs
  • Identifying the site’s relevant infrastructure, patient population and qualifications- what data should be collected by the sponsor?
  • Evaluating real-time feasibility
Oct 3012:45
Conference pass

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

Protein Engineering
  • Examined the role of IgG domains distal from the Fc in altering the affinity between IgG and FcRn
  • Identified that variable domains, and in particular complementarity-determining regions (CDRs), significantly alter binding affinity to FcRn in vitro and determined that affinity values correlated with calculated isoelectric point values
  • Demonstrated that tighter affinity values of IgG molecules to FcRn trend with faster in vivo clearance of a set of IgG molecules differing only by 1-3 mutations in human FcRn transgenic mice
Oct 3012:45
Conference pass

Reserved for supporting partner

Immunotherapy for solid tumours
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3012:45
Conference pass

Reserved for supporting partner

Manufacture, logistics and supply chain
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3012:45
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3012:45
Conference pass

Clinical development of patient-centric injectable biologics-device combination products

CMC and Developability
  • The development of drug-device combination (DDC) products is a strategic imperative across the biopharmaceutical industry for injectable biologics
  • A successful clinical strategy to address changes in manufacturing processes for drug substance as well as for DDC presentations needs to be risk-based and scientifically sound
  • An injectable DDC needs to be user-centric, and usability assessment in real-world clinical settings may be required to support the approval of a DDC
Oct 3012:45
Conference pass

HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species

Technology Showcase
Oct 3014:00
Conference pass

Data protection and outsourcing

Clinical Trials plenery
  • Although outsourcing these services is advantageous in many ways, what are the risks involved?
  • The importance of proactively selecting and tracking third party vendors on a regular basis before, during and after the completion of the contract
Tina Harris, Director Data Management, Amgen Inc
Oct 3014:20
Conference pass

Big data in designing clinical trials

Clinical Trials plenery
Reserved for supporting partner- If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:35
Conference pass

Genetic encoding of a cyclopropene for the rapid and efficient generation of stable antibody conjugates

Protein Engineering
  • Efficient transient and stable expression systems
  • Rapid conjugation of tetrazine-bearing molecules
  • Dihydropyridazine bond stability in serum
  • Generation of a potent and selective ADC
Oct 3014:35
Conference pass

Reserved for supporting partner

Combination therapy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:35
Conference pass

A year to review: 2018, more decisions, more launches, more unanswered questions

Track 1 - Biosimilar commercialisation
Oct 3014:35
Conference pass

Reserved for supporting partner

Manufacture, logistics and supply chain
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:35
Conference pass
Oct 3014:35
Conference pass

How unsafe are the new biosimilars really?

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • From theory to practice
  • The evolving evidence base
  • Closing the gap
  • Incremental risk vs expected risk
Oct 3014:35
Conference pass

Reserved for Supporting Partner

Armed Antibodies
if you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:35
Conference pass

CMC aspects of highly concentrated protein formulations

CMC and Developability
  • Why do we need HCLF?
  • How high is high?
  • CMC challenges
  • Some related case studies
Oct 3014:40
Conference pass

Title TBC

Clinical Trials plenery
Mats Sundgren, Director, Health Informatics, AstraZeneca
Oct 3014:55
Conference pass

Antibody protein sequencing with mass spectrometry

Protein Engineering
  • Robust service to routinely sequence antibodies proteins directly
  • Accurate determination of Isoleucine and Leucine using mass spectrometry
  • Beyond 100% protein coverage by examine individual amino acid
Oct 3014:55
Conference pass

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3lg or Eftilagimod Alpha) as an antigen pres

Combination therapy
  • Understand the rationale for combining an APC activator (LAG-3lg or “efti”) with an immune checkpoint inhibitor (anti-PD-1 pembrolizumab)
  • Pharmacodynamic effects of efti (6 or 30 mg s.c.) in patients
  • Highlighting in vitro and in vivo preclinical data along with emerging clinical data
Oct 3014:55
Conference pass

Reserved for supporting partner

Manufacture, logistics and supply chain
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:55
Conference pass

Reserved for Supporting Partner

Bispecifics
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:55
Conference pass

Reserved for Supporting Partner

CMC and Developability
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3014:55
Conference pass

Continuous bioprocessing: how to prepare for process efficiency in early stage process development

Technology Showcase
  • Using Quality by Design (QbD) principles for process design in early stage (continuous) process development
  • Process Failure Mode and Effect Analysis to identify risks and define mitigation strategies
  • Scale-up/scale-down considerations for continuous downstream processing
  • Bioburden control and virus safety strategies in continuous downstream processing
Oct 3015:00
Conference pass

Advanced therapeutics inference by high-dimensional analytics

Clinical Trials plenery
  • A novel approach: high-dimension model
  • Big data in clinical environment
  • Machine learning applied in clinical studies
  • Improving clinical trials
Oct 3015:00
Conference pass

How to navigate the IP and legal landscape when launching a biosimilar

Track 1 - Biosimilar commercialisation
Speaking slot available
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3015:00
Conference pass

WHO International Standards for Biosimilars

Track 2 - Biosimilar Sustainability/Development and manufacturing
  • Infliximab study
  • Future plans for biosimilar standards from the WHO
  • Harmonizing immunogenicity testing
Meenu Wadhwa, Section Leader for Cyotkines and Growth Factors Section, NIBSC
Oct 3015:15
Conference pass

Fighting pathogens and toxins with human and human-like antibodies

Protein Engineering
  • Recombinant antibodies for biodefense
  • Neutralizing and protective antibodies against viruses (Marburg virus, VEEV and WEEV)
  • Neutralizing and protective antibodies against toxins (botulinum toxins, diphtheria toxin)
  • Germline humanization of macaque antibodies
Oct 3015:15
Conference pass

IgA as novel antibody format for lymphoma and neuroblastoma is enhanced by myeloid checkpoint inhibitors

Combination therapy
  • IgA recruits neutrophils as effector cells for treatment of cancer
  • Preclinical evidence for mode of action of IgA
  • Adverse effect for neuroblastoma treatment is eliminated with IgA
  • Blocking CD47/SIRPα axis strongly enhances IgA effects
Oct 3015:15
Conference pass

CD47 targeting bispecific antibodies

Bispecifics
  • Rationale for CD47 neutralization in cancer
  • Targeting CD47 with bispecific vs monoclonal antibodies – what’s the difference?
  • Blockade of CD47 with bispecific antibodies promotes tumour elimination in vivo and modifies the tumour microenvironment
Oct 3015:15
Conference pass

State of the art manufacture for cellular immunotherapy

Manufacture, logistics and supply chain
Mayo Pujols, VP Global CAR-T Operations & Technology, Celgene
Oct 3015:15
Conference pass

Reserved for Supporting Partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3015:15
Conference pass

An integrated approach to assess the developability of biologics

CMC and Developability
Oct 3015:15
Conference pass

Reserved for Supporting Partner

Technology Showcase
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3015:25
Conference pass

Panel: Legal and IP strategies to strengthen biosimilar medicine developers

Track 1 - Biosimilar commercialisation
Oct 3015:25
Conference pass

Originator and biosimilar mAbs and Fc-fusion state-of-the art analytical methods

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 3015:35
Conference pass

Harnessing biotechnology against snakebite and other neglected tropical diseases

Protein Engineering
  • Snake venoms - a diverse arsenal of highly potent protein-based toxins
  • Cocktails of monoclonal human IgG antibodies with in vivo efficacy against snake venoms
  • Discovery of neurotoxin-targeting human IgGs using phage display technology
  • Using snake venom toxins to target parasitic diseases
Oct 3015:35
Conference pass

NKTR-214 in combination with OPDIVO® (nivolumab)

Combination therapy
Deborah Charych, Executive Director, Nektar Therapeutics
Oct 3015:35
Conference pass

Reserved for supporting partner

Manufacture, logistics and supply chain
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3015:35
Conference pass

Reserved for Supporting Partner

Bispecifics
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3015:35
Conference pass

Improving single-cell delivery of antibody and protein-drug conjugates: Multiple strategies to increase drug distribution and efficacy

Armed Antibodies
  • The distribution of cytotoxic payloads from antibody drug conjugates within a tumor, not just the total amount of payload, has a significant impact on efficacy
  • Multiple strategies can improve tumoral distribution including target selection, protein structure, and dosing to increase efficacy
  • These approaches and relevant examples will be discussed in the context of when each strategy is appropriate
Oct 3015:35
Conference pass

The applications of charge based analytical methods in bioprocess development

CMC and Developability
  • cIEF method for purity analysis of mAbs
  • AEX method for analysis of tyrosine sulfation of a mAb
  • CEX method as process analytical technology tool (PAT)
Oct 3015:35
Conference pass

Reserved for Supporting Partner

Technology Showcase
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3016:30
Conference pass

Panel Discussion: The importance of clinical data sharing

Clinical Trials plenery
  • How the value of clinical trials data can be maximised through sharing platforms
  • Challenges around globalising data sharing
  • Data access and analysis
Niels Grabe, Director, Tissue Imaging and Analysis Center, University of Heidelberg Medical Center
Jennifer O'Callaghan, Clinical Data Sharing Manager, Wellcome Trust
Oct 3017:00
Conference pass

Increasing the therapeutic window and pharmacokinetics

Keynotes
Oct 3017:00
Conference pass

Driving high T-cell titers to neoantigens in tumours – harnessing immunogenic viral vectors with immune check point modulators

Neoantigens
  • DNA damage may cause mutations in tumours that can generate new antigens, known as tumour-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumour microenvironment
Oct 3017:00
Conference pass

Implementation and administration of biosimilars in the clinic

Track 1 - Biosimilar commercialisation
Kalveer Flora, Specialist Pharmacist Rheumatology & Biosimilars, London North West Healthcare Nhs Trust
Oct 3017:00
Conference pass

Targeting combined treatments to arthritic joints by antibody-specific to damaged cartilage: a safer therapy platform for rheumatoid arthritis

Immunotherapy for non-oncology
  • There are 40% of patients with rheumatoid arthritis that do not respond to treatments
  • A major issue with systemic treatment due to side effects
  • We developed a platform that can address these unmet needs by:
    • Targeting treatments to the disease tissue
    • Utilize the efficacy of combined biologics which could otherwise lead to major advert effects if administered systemically
Oct 3017:00
Conference pass

Case studies of issues that occurred during the development of biosimilar products

Track 2 - Biosimilar Sustainability/Development and manufacturing
Oct 3017:10
Conference pass

Managing an effective clinical supply chain process

Clinical Trials plenery
  • Aspects to consider when supply planning
  • Influence of early decisions and impact on outcome as trial progresses
  • How decisions may/may not put patients and the trial at risk
Oct 3017:20
Conference pass

CMC strategies to influence pharmacokinetics

Keynotes
  • Mechanisms influencing the pharmacokinetics of antibodies
  • API-related critical quality attributes influencing pharmacokinetics
  • Considerations for antibodies with and without effector function
Oct 3017:20
Conference pass

Reserved for supporting partner

Neoantigens
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3017:25
Conference pass
Oct 3017:30
Conference pass

From tendering to long term partnership in CTS

Clinical Trials plenery
  • Using data to improve trial accuracy
  • Forecasting systems: react to fluctuations in the supply chain and enable you to act in real time
  • Considerations of whether to build an internal forecasting system or rely on third party software?
Oct 3017:40
Conference pass

Safety testing of monoclonal antibodies: new targets, new molecules, new challenges

Keynotes
  • In silico review of target biology
  • Rationale mAb design/selection to avoid unwanted biological/immune effects
  • In vitro studies: pharmacology/immunosafety studies to characterise Fab and Fc effects, off-target binding and immunogenicity
  • In vivo studies: safety/efficacy/PD studies in normal/disease models
  • Using safety, PK/PD and M&S data to select safe human starting doses and escalation schemes
Oct 3017:40
Conference pass

Development of a cost-effective personalized cancer neoantigen vaccines inducing a unique CD8-dominated T cell response

Neoantigens
  • Potentiating vaccines by attracting, activating and delivering antigens to antigen presenting cells
  • Targeting results in a unique CD8-dominated T cell response.
  • DNA vaccine format allows a rapid, cost-effective and robust manufacturing process viable for manufacturing patient-specific vaccines on demand
  • A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is ongoing
Oct 3017:40
Conference pass

Proteomics crashes at the intersection of autoimmunity and cell biology

Immunotherapy for non-oncology
  • Review novel protein modifications that trigger autoimmune responses and pathology
  • Discuss proteins modifications that also alter cell biology and metabolism
  • Protein biomarkers as indicators of disease progression and therapeutic strategies
Oct 3017:50
Conference pass

How can technology be used to track clinical supplies?

Clinical Trials plenery
Reserved for supporting partner- If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3018:00
Conference pass

Direct quantitation of therapeutic sntibodies for pharmacokinetic studies using immuno-purification and intact mass analysis

Keynotes
  • PK of mAbs has traditionally been measured using ligand binding assays
  • The use of mass spectrometry can complement LBA results
  • Results comparing LC-MS with LBA will be presented from GLP studies
Oct 3018:00
Conference pass

Individualized therapeutic cancer vaccines – How to select for immunogenic neoantigens?

Neoantigens
  • Selecting the right tumour specific antigens - the key for successful therapeutic T cell cancer vaccines
  • Bypassing prediction - identification of tumour specific T cell antigens by a functional readout
  • Vaccination with common tumour antigens - decoding the “Mutanome” presented on HLAs
Oct 3018:00
Conference pass

Combinatorial therapeutic HIV-1 vaccines: Time for immune checkpoint inhibitors

Immunotherapy for non-oncology
  • Talk will focus on HIV-1 infected and treated patients who received therapeutic vaccination
  • Discuss the current work on how to improve therapeutic vaccination using immune checkpoint inhibitors
Oct 3018:15
Conference pass

Closing remarks from chair

Keynotes
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Oct 3018:20
Conference pass

Reserved for Supporting Partner

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3018:20
Conference pass

Reserved for supporting partner

Neoantigens
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3018:20
Conference pass

Regulatory T-cells for autoimmune disease

Immunotherapy for non-oncology
David Klatzmann, Professor, Pierre et Marie Curie University and Medical School

Create your personal agenda –check the favourite icon

Oct 3109:00
Conference pass

Chairs Opening Remarks

Keynotes
Peter Marshall, Principal Technology Engineer, AstraZeneca
Oct 3109:05
Conference pass

Designing to a limit or a band –Interpretation and design challenge

Keynotes
Peter Marshall, Principal Technology Engineer, AstraZeneca
Oct 3109:20
Conference pass

Improving the effectiveness of anti-cancer mAb

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3109:40
Conference pass

Fc-Optimized anti-CD25 depletes tumour-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumours

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3109:45
Conference pass

Keynote panel discussion: Current challenges and trends in the HPAPI community

Keynotes
  • Pros and cons of hazard and control banding
  • What does risk based approach mean in practice
  • Is one approach feasible for the industry?
Martin Axon, Principal, Occupational Hygienist of Operations for Europe, Safebridge
Marc Abromovitz, Head, Industrial Hygiene, Novartis
Wendel Doubleday, Senior Director of Chemical Development, Seattle Genetics Inc
Oct 3110:00
Conference pass

Bispecific and bifunctional fusion proteins

Keynotes
  • Concept of bispecific and bifunctional fusion proteins
  • Bispecific antibodies for dual targeting
  • Dual-acting costimulatory fusion proteins
  • Hexavalent death ligand fusion proteins
Oct 3110:20
Conference pass

Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anti-cancer immunity

Keynotes
  • Changes of glycans in the tumor microenvironment
  • Upregulation of sialoglycans increase density of ligands for Siglec receptor
  • Siglec receptors are new immune checkpoints upregulated on tumor-infiltrating T cells
  • Siglec-sialoglycan interactions can be targeted to improve anti-cancer immunity
Oct 3111:20
Conference pass

Biomarker-directed drug development in oncology

Novel targets and biomarker discovery
Oct 3111:20
Conference pass

Universal allosteric switch modules to regulate antibody affinities

Antibody screening and immune repertoire sequencing
  • Antibody affinities in FACS were regulated by a linker-based allosteric effector domain
  • Validated with 5 different svFv so far
  • Works both in VH-VL / VL-VH orientation
  • Regulation under physiological conditions (no ion concentration change)
Oct 3111:20
Conference pass

Experimental and computational profiling of Biologics: a powerful duo for next generation developability

Computational discovery and development
  • Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development
  • Developability assessment at Novartis combines information about expression, aggregation propensity, process fit, stability, solubility, physicochemical properties, in vivo fitness and immunogenicity of potential candidates
  • This integrated approach prior to lead selection provides a thorough, yet resource efficient approach
Oct 3111:20
Conference pass

Antibody discovery and engineering in mammalian cells by homology-directed mutagenesis

Research hub
  • Optimizing conditions for homology-directed mutagenesis in mammalian cells
  • Designing, generating, and analyzing synthetic antibody libraries
  • Full-length antibody screening and affinity maturation in mammalian cells
  • Deep mutational scanning in mammalian cells by combining homology-directed mutagenesis and deep sequencing
Oct 3111:40
Conference pass

Deep sequencing analysis of phage selection outputs: Leaving conventional screening behind

Antibody screening and immune repertoire sequencing
  • We will show adaptations to library design and panning strategies exploiting the full potential of deep sequencing analysis of phage selection output pools to identify high affine antibodies without conventional screening
Oct 3111:40
Conference pass

A computational framework for predicting protein liabilities & improvement of antibody developability

Computational discovery and development
  • AggScore: a new method to identify aggregation hotspots on the interaction surface of proteins by evaluating hydrophobic, but also charged surface patches
  • BioQSPR: a machine-learning suite to generate prediction models to address issues like aggregation, solubility, stability and viscosity
Oct 3111:40
Conference pass

Targeting the inside of the cell with antibodies

Research hub
  • Approaches to target the inside of the cell
  • Knockdown of various membrane receptors with intrabodies
  • Intrabody mediated knockdown in mice
Oct 3111:45
Conference pass

Key challenges in rolling out an HPAPI project

Keynotes
Justin Mason-Home, Director, HPAPI Services Limited
Oct 3111:45
Conference pass

Process equipment integration into HPAPI’s containment systems –from R&D to production scale

Keynotes
Stefano Butti, Head of Sales Group, F.P.S. Food and Pharma Systems Srl
Oct 3111:45
Conference pass

PDC*line Pharma semi-allogeneic cancer vaccine: how abortive allogeneic immune response can prime and boost the induction of specific anti-tumor T cells

Cancer vaccines
  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • The technology can be applied for any type of cancer
Oct 3111:45
Conference pass

Tolerogenic nanoparticles to mitigate immunogenicity and improve the efficacy of immunotoxins for cancer therapy

Safety and efficacy
  • The development of anti-drug antibodies (ADAs) can compromise the efficacy and safety of biologic therapies
  • Recombinant immunotoxins are potent but highly immunogenic anti-cancer agents
  • We have partnered with the National Cancer Institute to demonstrate that synthetic vaccine particles nanoparticles containing rapamycin (SVP-Rapamycin) effectively mitigate ADAs against LMB-100, a mesothelin-targeted immunotoxin, and enables robust anti-tumor responses in preclinical models
  • The combination of LMB-100 and SVP-Rapamycin is currently in clinical trials for the treatment of patients with mesothelioma
Oct 3112:00
Conference pass

Title TBC

Novel targets and biomarker discovery
Andre Choo, Principal Scientist and Director, Antibody Discovery, Bioprocessing Technology Institute
Oct 3112:00
Conference pass

Reserved for supporting partner

Computational discovery and development
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3112:00
Conference pass

Moving forward with adoptive transfer of expanded tumour-infiltrating lymphocytes (TIL) scientifically and in clinical practice

Research hub
  • Determination of TIL quality and potential after initial harvesting
  • Effector phenotype of lymphocytes after excision and before infusion
  • Effect of serum and serum free medium on T lymphocytes
  • Timing and quantity of addition of antibodies to the TIL production
Julia Manzetti, PostDoc, Head of production of TILs, University Hospital Basel
Oct 3112:05
Conference pass

Cell penetrating peptides and TLR peptide agonist: the swiss army knife of cancer vaccines

Cancer vaccines
  • Therapeutics cancer vaccines
  • Chimeric proteins
  • Multi-antigenic T cells immunity responsive
Oct 3112:05
Conference pass

Reserved for supporting partner

Safety and efficacy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3112:20
Conference pass

Brain delivery and intracellular sorting of affinity variants of the anti-TfR antibody OX26

Novel targets and biomarker discovery
  • Antibody engineering has been used to create affinity variants of the mouse anti-rat transferrin receptor antibody OX26
  • We found an inverse correlation between antibody affinity and brain penetration, and efficacy in a model of inflammatory pain when coupled to the peptide galanin
  • Cell fractionation revealed the affinity variants had different intracellular fates, helping us understand how changes in affinity improve brain exposure
Oct 3112:20
Conference pass

Droplet-microfluidics in antibody discovery and immunoncology

Antibody screening and immune repertoire sequencing
  • New 2-cell platform enabling the screening of antibodies for their effect on target cells
  • Compatible with difficult targets such as GPCRs
  • Complementary platform for the stratification of cancer patients for personalized treatments
  • Results are available within 24h after surgery/biopsy at very competitive screening costs
Oct 3112:20
Conference pass

Reserved for Supporting Partner

Computational discovery and development
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3112:20
Conference pass

Design and development of mammalian cell perfusion cultures for end-to-end continuous biomanufacturing

Research hub
  • Perfusion scale down model, Process development strategy
  • Improve media utilization efficiency
  • Process optimization
Oct 3112:25
Conference pass

Reserved for Supporting Partner

Cancer vaccines
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3112:25
Conference pass

Predicting and mediating CAR, TCR and TIL toxicities

Safety and efficacy
Saad Kenderian, Assistant Professor of Medicine, Oncology, and Immunology Director, T Cell Engineering Program, Mayo Clinic
Oct 3112:40
Conference pass

Towards a therapy of neurodegenerative diseases - a lesson learned from prion diseases

Novel targets and biomarker discovery
  • Neurodegenerative diseases
  • Prion diseases
  • Alzheimer's disease
  • Shed PrP, PrP226
  • Monoclonal antibody, scFv
  • BBB
  • Cell-penetrating peptide
Oct 3112:40
Conference pass

MemoMAB: Antibody repertoires

Antibody screening and immune repertoire sequencing
  • Immune repertoire analysis and antibody discovery from human donors and animals
  • Repertoire biobanking in a screenable format using mammalian cell display
  • High fidelity and rapid turn-over times
Oct 3112:40
Conference pass

The sequence space of antibody repertoires

Computational discovery and development
  • The sequence space that entire antibody repertoires cover is best investigated with large-scale networks
  • The sequence space architecture of antibody repertoires is reproducible, robust and redundant
  • Prospective on the predictability of evolutionary pathways in sequence space
Oct 3112:40
Conference pass

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones

Research hub
  • Introduction to disulfide rebridging as a strategy for the synthesis of homogenous bioconjugates
  • Introduction to dibromopyridazinediones as a conjugation reagent for disulfide rebridging
  • Exploring optimal conjugation conditions for achieving maximum homogeniety across multi-disulfide systems (especially IgG1 Abs)
  • Exploring the effect of disulfide rebridging on antibody activity, with focus towards Fc interactions
Oct 3112:45
Conference pass

Reserved for supporting partner

Cancer vaccines
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3112:45
Conference pass

Reserved for supporting partner

Safety and efficacy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3113:05
Conference pass

Reserved for supporting partner

Cancer vaccines
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3113:05
Conference pass

Reserved for supporting partner

Safety and efficacy
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3113:30
Conference pass

Control banding-the power of hypnosis

Toxicology and EHS
Marc Abromovitz, Head, Industrial Hygiene, Novartis
Oct 3113:30
Conference pass

Batch vs continuous manufacturing

Manufacturing and Scaling up
Alessandro Brigo, Principal Scientist in Pharma Research and Early Development and Toxicology Project Leader, Roche Pharmaceuticals
Oct 3113:50
Conference pass

Toxicology and acceptable daily exposure limits

Toxicology and EHS
Ester Lovsin Barle, Corporate Toxicologist, Lonza
Oct 3113:50
Conference pass

Scaling up from pilot plant

Manufacturing and Scaling up
Andreas Schreiner, Director of Validation, Manufacturing Science and Technology, Novartis Ag
Oct 3114:00
Conference pass

Antibodies as drugs: Pursuit of the ‘high hanging fruit’

Keynotes
  • Opportunities and challenges with antibody drugs
  • Applications of bispecific antibodies
  • Efficient production of bispecific IgG in single host cells
Oct 3114:10
Conference pass

Panel discussion- risk assessment

Toxicology and EHS
  • Hazard and process information
  • What to consider for a good quality PDE document?
Andreas Schreiner, Director of Validation, Manufacturing Science and Technology, Novartis Ag
Oct 3114:10
Conference pass

Knowledge hubs and social centres to increase HPAPI understanding

Manufacturing and Scaling up
Nigel Saunders, SME Containment, GSK
Oct 3114:20
Conference pass

Evolution and advancements in cancer immunotherapy

Keynotes
Partha Chowdhury, Senior Director and Head, Antibody Discovery, Sanofi Genzyme
Oct 3114:20
Conference pass

Reserved for Supporting Partner

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3114:25
Conference pass

Patient selection strategies for making precision medicine a reality in immuno-oncology

Keynotes
Oct 3114:30
Conference pass

Case study – bringing contained ways of working to an oral solid dosage form pilot plant

Manufacturing and Scaling up
Oct 3114:45
Conference pass

The future of precision medicine

Keynotes
  • Oncology and genomics: halfway there
  • Immunology and more Omics: we’re just starting
  • The future: complexity simplified, research put into practice, digital put into action
Oct 3115:00
Conference pass

Reserved for Supporting Partner

Keynotes
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Oct 3115:20
Conference pass

Practical handling of HPAPI within Sandoz API

Toxicology & EHS
Jerome Cluzeau, Senior Scientist, Lek Pharmaceutical
Oct 3115:20
Conference pass

Using AI in manufacture and scale up

Manufacturing and Scaling up
Alessandro Brigo, Principal Scientist in Pharma Research and Early Development and Toxicology Project Leader, Roche Pharmaceuticals
Oct 3115:40
Conference pass

Drug safety surveillance in multiple principal interrelated areas

Toxicology & EHS
Jorge González Borroto, Pharmacovigilance Officer/Senior Toxicologist, Ferrer Internacional, S.A.
Oct 3115:40
Conference pass

Sponsor Available

Manufacturing and Scaling up
for more information please contact Alistair Wilmot:
E: alistair.wilmot@terrapinn.com
T: +44 (0) 207 092 1174
Oct 3116:00
Conference pass

Single use vs multi use containment bagged manufacture- Pros and Cons

Toxicology & EHS
Jonathan Bones, Principal Investigator, NIBRT
Oct 3116:00
Conference pass

Use of AMBR 250 in bioreactors to produce isotopically ladled Antibodies

Manufacturing and Scaling up
Sung-Hye Grieco, Senior Engineer at Early Stage Cell Culture, PTD Department, Genetech
last published: 13/Jul/18 09:55 GMT

 

 

APPLY TO SPEAK

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates